Literature DB >> 12218210

Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases.

Melissa H Cessna1, Holly Zhou, Warren G Sanger, Sherrie L Perkins, Sheryl Tripp, Diane Pickering, Clark Daines, Cheryl M Coffin.   

Abstract

Abnormalities of chromosome 2p23 with expression of ALK1 and p80 occur in both inflammatory myofibroblastic tumor (IMT) and anaplastic large cell lymphoma. This immunohistochemical study investigates whether the ALK family of neoplasms includes fibroblastic-myofibroblastic, myogenic, and spindle cell tumors. Formalin-fixed paraffin-embedded archival tissues from 10 IMTs and 125 other soft tissue tumors were stained for ALK1 and p80 with standard immunohistochemistry. ALK1 and/or p80 reactivity was observed in a cytoplasmic pattern in IMT (4/10; 40%), malignant peripheral nerve sheath tumor (4/10; 40%), rhabdomyosarcoma (6/31; 19%), leiomyosarcoma (1/10; 10%), and malignant fibrous histiocytoma (1/11; 9%). No staining was observed in nodular fasciitis, desmoid, infantile myofibromatosis, infantile fibrosarcoma, synovial sarcoma, leiomyoma, or myofibrosarcoma. Alveolar rhabdomyosarcomas (4/16; 25%) displayed a distinctive dot-like cytoplasmic positivity. No cases displayed nuclear reactivity. Fluorescent in situ hybridization on 12 of the positive cases revealed a combination of abnormalities including ALK break-apart signals, nucleophosmin (NPM)/ALK fusions, or extra copies of 2p23. This study demonstrates that in addition to IMT, abnormalities of ALK1 and p80 expression with a variety of structural chromosomal changes are found in several sarcomas, especially rhabdomyosarcoma and malignant peripheral nerve sheath tumor. Although immunoreactivity in non-IMTs cannot distinguish between structural abnormalities involving 2p23 or additional copies of 2p23, it supports the concept of ALK involvement in a larger group of neoplasms, some of which have other documented clonal abnormalities. In IMT, immunohistochemistry for ALK1 and p80 is useful as an indicator of a 2p23 abnormality, but it must be interpreted in the context of histologic and other clinicopathologic data if used as an adjunct to differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218210     DOI: 10.1097/01.MP.0000026615.04130.1F

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  73 in total

1.  Inflammatory myofibroblastic tumor of the lung: a benign lesion with aggressive behavior.

Authors:  Sonia Ezzine-Baccari; Dhouha Bacha; Sélim Sassi; Maher Abouda; Hédia Ghrairi; Hassen Touinsi; Sadok Sassi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-06-06

2.  Inflammatory pseudotumor of the liver and spleen diagnosed by percutaneous needle biopsy.

Authors:  Tsukasa Kawaguchi; Kiyoshi Mochizuki; Takashi Kizu; Masanori Miyazaki; Takayuki Yakushijin; Shusaku Tsutsui; Eiichi Morii; Tetsuo Takehara
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

3.  Soft-tissue inflammatory myofibroblastic tumors (IMTs) of the limbs: potential and limits of diagnostic imaging.

Authors:  Carlo Masciocchi; Giuseppe Lanni; Laura Conti; Armando Conchiglia; Eva Fascetti; Stefano Flamini; Gino Coletti; Antonio Barile
Journal:  Skeletal Radiol       Date:  2011-09-24       Impact factor: 2.199

4.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

5.  Abdominal inflammatory masses mimicking neoplasia in children-experience of two centers.

Authors:  Piotr Czauderna; Klaus Schaarschmidt; Leszek Komasara; Dieter Harms; Michael Lempe; Klaus Vorpahl; Malgorzata Szumera; Alicja Balanda
Journal:  Pediatr Surg Int       Date:  2005-04-07       Impact factor: 1.827

6.  Omental mesenteric myxoid hamartoma, a subtype of inflammatory myofibroblastic tumor? Considerations based on the histopathological evaluation of four cases.

Authors:  K Ludwig; R Alaggio; P Dall'Igna; E Lazzari; E S G d'Amore; P M Chou
Journal:  Virchows Arch       Date:  2015-09-19       Impact factor: 4.064

7.  Morphologic Overlap Between Inflammatory Myofibroblastic Tumor and IgG4-related Disease: Lessons From Next-generation Sequencing.

Authors:  Martin S Taylor; Abhijit Chougule; Allsion R MacLeay; Pawel Kurzawa; Ivan Chebib; Long Le; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2019-03       Impact factor: 6.394

8.  Inflammatory pseudotumor of the thyroid gland showing prominent fibrohistiocytic proliferation. A case report.

Authors:  Masaru Kojima; Masami Suzuki; Kazuhiko Shimizu; Nobuhide Masawa
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  Molecular diagnosis in lymphoma.

Authors:  Adam Bagg
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.